• Markets
  • icon
  • Companies
OSL · ASX

OncoSil Medical Ltd (ASX:OSL)

AU$0.005

 0.0 (0.0%)
ASX:Live
17/05/2024 04:10:34 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

OSL Overview

OSL Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About OSL

Telephone

Address

Description

OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. It engages in the development of novel and safer radiation therapy treatments. The company was founded by David McAuliffe on April 14, 2005 and is headquartered in North Sydney, Australia.

OSL Price Chart

Key Stats

Market Cap

AU$16.59M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.01

Trade Value (12mth)

AU$5,596.00

1 week

25%

1 month

-28.57%

YTD

-41.18%

1 year

-55.88%

All time high

0.20440100133419037

Key Fundamentals

EPS 3 yr Growth

92.300%

EBITDA Margin

%

Operating Cashflow

-$11m

Free Cash Flow Return

-106.70%

ROIC

-107.00%

Interest Coverage

-1,135.60

Quick Ratio

7.20

Other Data

Shares on Issue (Fully Dilluted)

2092m

HALO Sector

Next Company Report Date

22-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

OSL Announcements

Latest Announcements

Date Announcements

15 May 24

Results of Meeting

×

Results of Meeting

15 May 24

Application for quotation of securities - OSL

×

Application for quotation of securities - OSL

15 May 24

Notification regarding unquoted securities - OSL

×

Notification regarding unquoted securities - OSL

10 May 24

Application for quotation of securities - OSL

×

Application for quotation of securities - OSL

10 May 24

Notification regarding unquoted securities - OSL

×

Notification regarding unquoted securities - OSL

08 May 24

Application for quotation of securities - OSL

×

Application for quotation of securities - OSL

08 May 24

Notification regarding unquoted securities - OSL

×

Notification regarding unquoted securities - OSL

03 May 24

Application for quotation of securities - OSL

×

Application for quotation of securities - OSL

03 May 24

Notification regarding unquoted securities - OSL

×

Notification regarding unquoted securities - OSL

02 May 24

$5.3 million raised under Entitlement Offer

×

$5.3 million raised under Entitlement Offer

02 May 24

Application for quotation of securities - OSL

×

Application for quotation of securities - OSL

02 May 24

Notification regarding unquoted securities - OSL

×

Notification regarding unquoted securities - OSL

01 May 24

1st Study in Man Increases Pancreatic Tumor Vascularity

×

1st Study in Man Increases Pancreatic Tumor Vascularity

30 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

17 April 24

Two more PANCOSIL Trial treatments using OncoSil device

×

Two more PANCOSIL Trial treatments using OncoSil device

16 April 24

Notice of Extraordinary General Meeting/Proxy Form

×

Notice of Extraordinary General Meeting/Proxy Form

16 April 24

First patient treated with OncoSil device in Turkiye

×

First patient treated with OncoSil device in Turkiye

12 April 24

First patient treated in the UK for the TRIPP-FXX study

×

First patient treated in the UK for the TRIPP-FXX study

09 April 24

UK Private Insurer Approves Reimbursement for OncoSil

×

UK Private Insurer Approves Reimbursement for OncoSil

05 April 24

First Austria-based treatments utilising the OncoSil device

×

First Austria-based treatments utilising the OncoSil device

04 April 24

Dispatch of Entitlement Offer Prospectus

×

Dispatch of Entitlement Offer Prospectus

28 March 24

Application for quotation of securities - OSL

×

Application for quotation of securities - OSL

28 March 24

Notice under section 708A

×

Notice under section 708A

25 March 24

Prospectus - Entitlement Offer

×

Prospectus - Entitlement Offer

22 March 24

Update - Proposed issue of securities - OSL

×

Update - Proposed issue of securities - OSL

OSL Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -96.2 -4.9 6.5 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -64.2 21.9 32.4 Lock Lock Lock
     Yield % Lock Lock Lock Lock -20.5 -31.2 -83.9 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.01 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.5 -22.3 -45.3 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 1,019 998 1,130 Lock Lock Lock
Basic m Lock Lock Lock Lock 1,019 998 1,130 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A 8.8 58.6 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 5 5 6 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -6 -7 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -4,071.3 -8.0 3.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -2,922.6 -2,902.2 -1,766.3 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 3,023 3,002 1,866 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -11 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -62.1 1.4 -9.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5,370.2 -4,867.5 -3,366.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -12 -11 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -61.3 1.9 -10.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5,457.0 -4,922.3 -3,414.3 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -12 -12 -12 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -10 -11 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -144.8 -2.8 -5.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -4,896.8 -4,627.8 -3,085.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -9 -10 -11 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 9 9 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -9 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -98.1 -14.1 -12.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -41.6 -43.6 -30.9 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 12 11 9 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 14 13 11 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -12 -11 -9 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 12 11 10 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 12 11 10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -45.1 -6.0 -12.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -73.7 -82.1 -98.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -89.2 -96.1 -114.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -68.0 -96.5 -116.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -61.5 -92.0 -107.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -52.0 -86.7 -106.7 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -726.6 -574.9 -1,135.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.0 1.0 0.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -100.5 -98.3 -93.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 6.4 7.2 7.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 6.4 7.2 7.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 89.9 88.5 83.6 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -413.3 -571.9 -721.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.1 0.2 0.3 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 575.8 401.7 261.1 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -5,402.3 -4,986.6 -3,384.1 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -81.3 -88.4 -108.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -73.7 -82.1 -98.9 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.2 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -89.2 -96.1 -114.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -89.2 -96.1 -114.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 3,415.1 1,644.9 1,088.7 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 3,415.1 1,644.9 1,088.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 73.2 56.6 50.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 3,342.0 1,588.3 1,038.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

OSL Shortsell

Frequently Asked Questions

The current share price of OncoSil Medical Ltd (OSL:ASX) is AU$0.005.
The 52-week high share price for OncoSil Medical Ltd (OSL:ASX) is AU$0.01.
The 52-week low share price for OncoSil Medical Ltd (OSL:ASX)? is AU$0.00.
OncoSil Medical Ltd (OSL:ASX) does not pay a dividend.
OncoSil Medical Ltd (OSL:ASX) does not pay a dividend.
OncoSil Medical Ltd (OSL:ASX) has a franking level of 0.0%.
OncoSil Medical Ltd (OSL:ASX) is classified in the Healthcare.
The current P/E ratio for OncoSil Medical Ltd (OSL:ASX) is .